BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/17/2022 2:00:49 AM | Browse: 748 | Download: 1833
 |
Received |
|
2021-11-21 18:53 |
|
Peer-Review Started |
|
2021-11-21 18:57 |
|
First Decision by Editorial Office Director |
|
2022-01-12 09:01 |
|
Return for Revision |
|
2022-01-12 09:01 |
|
Revised |
|
2022-01-24 05:43 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-04-12 01:58 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-04-21 19:31 |
|
Articles in Press |
|
2022-04-21 19:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-04-26 08:43 |
|
Publish the Manuscript Online |
|
2022-05-17 02:00 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Minireviews |
| Article Title |
Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jyoti bajpai, Akshyaya Pradhan, Ajay Kumar Verma and Surya Kant |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Surya Kant, FCCP, Professor, Department of Pulmonary Medicine, King George Medical University, Department of Pulmonary Medicine, King George Medical University, Lucknow, India. Electronic address: skantpulmed@gmail.com., lucknow 226003, uttar pradesh, India. skantpulmed@gmail.com |
| Key Words |
Hydroxychloroquine; Azithromycin; Antiviral effects; QT interval; Randomized controlled trial |
| Core Tip |
The coronavirus disease 2019 (COVID-19) pandemic has raged across the globe imposing a huge burden on the health systems. In absence of definitive treatment or vaccines, many drugs with antiviral properties were repurposed for use against COVID-19 infection. Based on the results of preliminary success in observational studies, Hydroxychloroquine (HCQS) and azithromycin were used extensively in the initial part of pandemic in he management of COVID-19 pandemic. Subsequently, reports of QT prolongation emerged with HCQS and its combination therapy with azithromycin. Later on HCQS was discontinued by major guidelines including World Health Organization. The review traces the emergence and downfall of the combination therapy in management of COVID-19. |
| Publish Date |
2022-05-17 02:00 |
| Citation |
Bajpai J, Pradhan A, Verma AK, Kant S. Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. World J Exp Med 2022; 12(3): 44-52
|
| URL |
https://www.wjgnet.com/2220-315x/full/v12/i3/44.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v12.i3.44 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
